Heart failure (HF) is a progressive condition with a clinical picture resulting from reduced
cardiac output (CO) and/or elevated left ventricular (LV) filling pressures (LVFP). The original …

Heart failure (HF) is the cause of impaired exercise capacity due to insufficient peripheral
blood flow. The development of natriuretic peptide (NP) through inhibition of the neprilysin …

Sacubitril/valsartan reduces heart failure (HF)-related hospitalizations and cardiovascular
mortality in PARADIGM-HF and has become a foundational treatment for HF with reduced …

Background The effects of sacubitril/valsartan (sac/val) on metabolic parameters and insulin
resistance (IR) in non-obese/prediabetic patients have not been previously described. Aim …

Background In patients with heart failure with reduced ejection fraction (HFrEF), treatment
with sacubitril–valsartan (S/V) may reverse left ventricular remodeling (rLVR). Whether this …

Aims We tested the hypothesis that initiation versus non-initiation of sacubitril/valsartan is
associated with a more favorable subsequent change in left ventricular ejection fraction …

Aims Conflicting results have been reported in the literature on the potential antiarrhythmic
effect of sacubitril/valsartan in heart failure patients with reduced ejection fraction (HFrEF) …

Of the various medical therapies for heart failure (HF), sacubitril/valsartan is a first-in-class
angiotensin receptor-neprilysin inhibitor that combines sacubitril, a pro-drug that is further …

Background: Existing studies have shown that sacubitril-valsartan ameliorated atrial
remodeling in atrial fibrillation (AF) and favored maintenance of sinus rhythm in patients with …

Aim Examine the performance of a simple echocardiographic" Killip score"(eKillip) in
predicting heart failure (HF) hospitalizations and mortality after index event of …